Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bigby, T.
Right arrow Articles by Matthay, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bigby, T.
Right arrow Articles by Matthay, M.

Chest, Vol 89, 435-439, Copyright © 1986 by American College of Chest Physicians

ARTICLES

Clinical spectrum of pulmonary mucormycosis

TD Bigby, ML Serota, LM Tierney Jr and MA Matthay

Pulmonary mucormycosis is an uncommon, but important, opportunistic fungal pneumonia which is often diagnosed post-mortem. This review emphasizes clinical and pathologic characteristics of pulmonary mucormycosis that differentiate this infection from other fungal pneumonias. The most common clinical presentation of pulmonary mucormycosis is a rapidly progressive pneumonia with diffuse infiltrates on chest radiographic examination of a patient with an underlying hematologic malignancy treated with immunosuppressive drugs. Other immunocompromised hosts at risk for pulmonary mucormycosis include patients with diabetes mellitus who may develop a distinctive endobronchial form of this disease. Early consideration of this diagnosis, along with aggressive diagnostic evaluation, are critical to effective therapy and patient survival. While treatment with amphotericin B is the mainstay of therapy for pulmonary mucormycosis, diabetics with endobronchial disease may benefit from early, aggressive surgical resection of the involved lung tissue.


This article has been cited by other articles:


Home page
 ChestHome page
D. R. Pauls, J. G. Ravenel, and M. A. Judson
A Neutropenic Patient With Rapidly Progressive Lung Lesion
Chest, October 1, 2004; 126(4): 1364 - 1367.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M.-L. Virally, J.-P. Riveline, J. Virally, P. Chevojon, J.-F. Regnard, A. Belmekki, and A. Devidas
Pulmonary Mucormycosis in a Diabetic Patient with HIV
Diabetes Care, November 1, 2002; 25(11): 2105 - 2105.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. A. Ribes, C. L. Vanover-Sams, and D. J. Baker
Zygomycetes in Human Disease
Clin. Microbiol. Rev., April 1, 2000; 13(2): 236 - 301.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
F. Y. W. Lee, S. B. Mossad, and K. A. Adal
Pulmonary Mucormycosis: The Last 30 Years
Arch Intern Med, June 28, 1999; 159(12): 1301 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S.J. Thaler and E.M. Bailey
Case 14-1996- A 66-year-old woman with toxic epidermal necrolysis and a fatal course
N. Engl. J. Med., May 9, 1996; 334(19): 1254 - 1261.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American College of Chest Physicians.